| 摘要 |
The invention relates to .gamma.-butyrobetaine and 3-(2,2,2- trimethylhydrazinium) propionate (Mildronate)-containing pharmaceutical compositions for oral, parenteral, subcutaneous or rectal administration for the treatment of heart-blood vessel diseases of various genesis and localization, blood circulation disturbances, stenocardia, myocardium infarction, arrhythmia, hypertension, myocarditis and low cardiac potency. This composition in the experiments on anaesthetized cats at a dose of 5 mg/kg of .gamma.-butyrobetaine + 5 mg/kg of Mildronate, i.v. increases a total blood flow by 18 %, blood pressure and heart rhythm being practically unchanged. The composition arrests adrenaline-induced blood vessel spasms in isolated rabbit ear, in a concentration of 2.0 .mu.M of .gamma.-butyrobetaine + 2.0 .mu.M of Mildronate, it decreases reperfusion pressure by 33 %. NO-synthase blocking essentially decreases the composition effect on adrenaline-induced blood vessel spasms. At a dose of 60 mg/kg of .gamma.-butyrobetaine + 40 mg/kg of Mildronate, the composition by 70 % declines mouse lethality from CaCl2- induced arrhythmia, and at a dose of 30 mg/kg of .gamma.-butyrobetaine + 30 mg/kg of Mildronate, p.o. by 60 % decreases rat lethality from CaCl2-induced arrhythmia. In the prophylactic and therapeutic regimens at a dose of 50 mg/kg of $(g)g-butyrobetaine + 50 mg/kg of Mildronate, the composition in the experiments on rats effectively prevents myocardium from occlusion-reperfusion- induced failures and ventricular fibrillations. In the comparative experiments the claimed composition demonstrates a more potent effect as compared with the known preparation Mildronate and .gamma.-butyrobetaine effects if they are applied separately. The composition is notable for a low toxicity and wide interval of therapeutic action safety.
|
